Zurich’s Aeon Acquires German Blood Diagnostics Platform Aware Health

Zurich-based Aeon has turned a seed extension into a double move: more money in the bank, and the core assets of German blood diagnostics platform Aware Health. The startup says the financing lifts its total seed round to more than USD 14 million, after the EUR 8.2 million it raised last year. The extension was co-led by Araya Ventures, with support from Concentric, GoHub Ventures, Kadmos Capital, N&V Capital, Bigwave Capital and Calm/Storm Ventures.

The purchase price was not disclosed. What Aeon did say is what it wants to do with the deal: fold Aware’s technology, team and customer data, with consent, into a product that combines whole-body MRI, blood diagnostics and AI. The company already sells whole-body check-ups that, by its account, can detect more than 500 possible anomalies through MRI, more than 100 biomarkers through blood tests, plus genetic risk analysis. Aeon says more than 90 percent of its check-ups already produce findings customers can act on, with a significant finding rate of 15.4 percent.

The strategic pitch is simple enough. MRI gives a snapshot. Blood values give a trend. Put them together quarter after quarter, and Aeon says it can build a living health record that AI can use to flag deviations early and predict individual risk. Founder and CEO Tim Seithe says the acquisition speeds that plan by two years. He also calls Aeon the first European platform to combine imaging and recurring blood diagnostics in one product.

Aware Health brings more than software. It ran a consumer blood diagnostics platform with live lab integrations and more than 45 blood-draw locations across Germany. The company says it served close to 10,000 active customers. Aeon is taking over the platform, key contracts, equipment, customer relationships and the core team, while the Berlin team stays on under the Aeon brand. Customer data will move only with explicit individual consent and in line with GDPR.

This is Aeon’s second acquisition. Last autumn it bought Swiss stealth company Holsain, and that deal brought in Florian Alexander Huber, who now serves as chief medical officer. Aeon is also adding Pablo Tano as AI lead. Araya Ventures’ Rupa Popat frames the bet as a rare one in Europe: imaging, recurring blood tests and AI in a single longitudinal picture. The funding numbers suggest the market is crowded, but Aeon is trying to win by stitching together pieces other startups keep selling separately.